Bitcoin ETFs Again Experience Extreme Caution from SEC




SEC Cryptocurrency ETFs are Not Getting Decided Upon on Schedule

 

The Securities and Exchange Commission (SEC) is requiring more time to review two Cryptocurrency ETFs that were nearing the agency’s decision dates. In its notice informing that it would need a longer period, the SEC indicated it was still reviewing issues raised during the comment period and that it maintains concerns over potential manipulation and bad actors.

The SEC gave notice in a filing on Monday (March 21) that it will delay the decision on an application by WisdomTree for a spot-based Bitcoin ETF. The original deadline was March 31; the SEC has now moved that out 45 days until May 15. The WisdomTree fund has been rejected by the agency before, back in December, it resubmitted a proposal in February and was approaching the original “decision date” of March 31. WisdomTree and others interested in the future of spot-based crypto ETFs now will have to wait up to another 45 days for an SEC approval or disapproval.

The regulator also gave itself 60 days after April 3 to decide on a proposal by One River Digital Asset Management for a fund it has proposed that tracks the price of Bitcoin adjusted for the carbon toll of mining tokens. The ETF would be called, One River Carbon Neutral Bitcoin Trust. The securitized trust would hold bitcoin and value its shares with an additional adjustment for the cost of offsetting carbon credits.


Excerpt: SEC Notice of Designation of a Longer Period for Commission Action on a Proposed Rule Change 3/21/22

The agency is apparently still grappling with concerns and prefers to err on the side of caution. It has indicated before that it isn’t comfortable with a Bitcoin ETF based on spot prices. The SEC has rejected several such applications, including an attempt by the corporate owners of the Grayscale Bitcoin Trust (GBTC) to convert that private-placement trust into an ETF. The Commission has said it is concerned with the lack of surveillance between the U.S. Securities regulators and the unregulated crypto markets.

One River is trying to address the SEC’s concerns by avoiding the issue of an ETF owning Bitcoin directly. Its proposed ETF wouldn’t buy, sell or hold Bitcoin directly through the spot market. Rather, it would use a creation-redemption process with “authorized participants” to guard against “bad actors” trying to manipulate prices and NAV calculations, according to its filing.

 

Take-Away

SEC Chairman Gary Gensler would prefer not to rush on approval of a novel Bitcoin ETF based on spot prices rather than futures contracts. The agency also delayed a similar decision on an application by Bitwise in February. Gensler, who taught cryptocurrency at MIT would prefer to take time and measure any concerns.  The agency did approve several futures-based crypto ETFs last Fall including The ProShares Bitcoin Strategy ETF (ticker: BITO), Valkyrie Bitcoin Strategy ETF (BTF), and VanEck Bitcoin Strategy ETF (XBTF).

 

Paul Hofman

Managing Editor, Channelchek

 

Suggested Reading



Imagine a Bitcoin ETF With No Underlying Bitcoin Assets



Stealth Digital Asset Bill Surprises Crypto Market





SEC Approves ETF for Bitcoin Revolution Investors



Cryptocurrencies and the Howey Test

 

Sources

https://www.sec.gov/rules/sro/cboebzx/2022/34-94476.pdf

https://www.sec.gov/Archives/edgar/data/1863687/000110465921070846/tm2116981d1_s1.htm

https://www.coindesk.com/markets/2021/05/24/asset-manager-one-river-files-for-carbon-neutral-bitcoin-etf-in-us/

https://www.theblockcrypto.com/linked/138680/sec-punts-on-wisdomtree-one-river-spot-bitcoin-etf-proposals

https://www.barrons.com/articles/sec-bitcoin-etfs-51647893798?mod=hp_LEAD_3

 

Stay up to date. Follow us:

 

Release – electroCore to Present at 2022 Maxim Virtual Growth Conference



electroCore to Present at 2022 Maxim Virtual Growth Conference

News and Market Data on electroCore

 

ROCKAWAY, N.J.
March 22, 2022 (GLOBE NEWSWIRE) — 
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer,  Dan Goldberger, will be presenting at the 2022 
Maxim Virtual Growth Conference.

electroCore’s presentation will be available on-demand from 
March 28th – 30th, 2022. To view the presentation, click HERE.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

Investors:
Rich Cockrell

CG Capital
404-736-3838
ecor@cg.capital

Pyxis Tankers (PXS) – Looking Ahead to Recovery With MR Tanker Focus

Tuesday, March 22, 2022

Pyxis Tankers (PXS)
Looking Ahead to Recovery With MR Tanker Focus

Pyxis Tankers Inc is a United States-based international maritime transportation company which focuses on the product tanker sector. It owns a fleet which comprises of double hull product tankers employed under a mix of short- and medium-term time charters and spot charters. The fleet owned by the company includes Pyxis Epsilon, Pyxis Theta, Pyxis Malou, Pyxis Delta, Northsea Alpha, and Northsea Beta. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, fuel oil, and other liquid bulk items, such as vegetable oils and organic chemicals.

Poe Fratt, Senior Research Analyst, Logistics, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Adjusted EBITDA loss of $0.7 million below expectations. Lower TCE revenue of $3.9 million, lower TCE rates of $8.0k/day and higher opex of $6.2k/day drove the negative EBITDA variance and adjusted 4Q2021 EBITDA losses of $0.7 million were below our estimate. The shift to spot market work dampened operating results, with MR weakness more than offsetting a slight improvement in small tankers.

    Recovery expected and our 2022 EBITDA estimate is $8.6 million.  Our 2022 TCE rate estimate is $13.4k/day and recent charters are setting a more positive tone heading into the rest of the year. In addition, the two acquisitions should more than offset the sale of the two small tankers. Forward cover visibility into 1Q2022 is solid at 83% of available days booked at TCE rates in the $14.8k/day range …


This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Euroseas (ESEA) – Adding Three New Build Feeders to Fleet Renewal Program

Tuesday, March 22, 2022

Euroseas (ESEA)
Adding Three New Build Feeders to Fleet Renewal Program

Euroseas Ltd. provides ocean-going transportation services worldwide. The company owns and operates containerships that transport dry and refrigerated containerized cargoes, including manufactured products and perishables; and drybulk carriers that transport iron ore, coal, grains, bauxite, phosphate, and fertilizers. As of March 31, 2017, it had a fleet of seven containerships; and six drybulk carriers, including three Panamax drybulk carriers, one Handymax drybulk carrier, one Kamsarmax drybulk carrier, and one Ultramax drybulk carrier. The company was founded in 2005 and is based in Maroussi, Greece.

Poe Fratt, Senior Research Analyst, Logistics, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Three new build Feeders added to fleet renewal program. Three Eco design 1,800 TEU Feeders will be built at Hyundai Mipo in South Korea for ~$102 million, or ~$34 million each, with deliveries are slated for 1H2024. The new build program expands to ~$264 million for seven Feeders. We view this move as another sign of confidence in the Feeder market outlook due to the below average order book compared to the order book for intermediate and larger containerships.

    First four Feeder new builds on track and time charter interest developing.  The first four Eco design 2,800 TEU Feeders ordered over the past three quarters are on track. Total estimated cost of first four Feeders is ~$161 million, with deliveries slated for 1Q2023/2Q2023/4Q2023/1Q2024. On the last earnings call, management indicated that there was budding interest in the first set of new builds …


This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Release – BioSig Technologies Inc. Announces $3 Million Financing with Family Office



BioSig Technologies, Inc. Announces $3 Million Financing with Family Office

News and Market Data on BioSig Technologies

 

Westport, CT, March 22, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it entered in a definitive purchase agreement for the sale of  $3 million of the Company’s common stock and warrants lead by a family office that has deep expertise in small cap emerging growth investing.  The closing of the offering is expected to occur on or about March 23, 2022, subject to the satisfaction of customary closing conditions.

Under the terms of the financing agreement, the Company will issue 2,611,739 shares of its common stock at a price of $1.15 per share and warrants to purchase 2,611,739 shares of the Company’s common stock at $1.40 per share.

BioSig intends to use the net proceeds from the offering to fund working capital and continue commercialization activities related to the PURE EP™ System.  This funding and its existing capital should provide sufficient operating capital for BioSig to execute its current business plan.

The offering is being made only by means of a prospectus supplement and accompanying base prospectus. The Company has filed a shelf registration on Form S-3 (File No. 333-251859) (including a base prospectus) with the U.S. Securities and Exchange Commission (“SEC”), which was declared effective on January 12, 2021. A final prospectus supplement and accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying base prospectus for the offering may also be obtained, when available, by contacting BioSig Technologies, Inc., 55 Greens Farms Road, Westport, CT 06880, Attention: Lora Mikolaitis; lmikolaitis@biosigtech.com. 

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the closing of the offering, (ii) the use of proceeds for the offering, (iii) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (iv) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (v) difficulties in obtaining financing on commercially reasonable terms; (vi) changes in the size and nature of our competition; (vii) loss of one or more key executives or scientists; and (viii) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119

Source: BioSig Technologies, Inc.

Release – Tonix Pharmaceuticals to Participate in the 2022 Virtual Growth Conference



Tonix Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Research, News, and Market Data on Tonix Pharmaceuticals

 

CHATHAM, N.J., March 22, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest.

The conference will take place March 28-30, 2022, with pre-recorded presentations available on-demand through the conference portal at 2022 Virtual Growth Conference and available under the IR Events tab of the Tonix website at www.tonixpharma.com. This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member here: Reserve Your Seat.

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, central nervous system (CNS) and infectious disease product candidates. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL2, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug in mid-Phase 3 development for the management of fibromyalgia, with a new Phase 3 study expected to start in the first half of 2022. TNX-102 SL is also being developed to treat Long COVID, a chronic post-COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the first half of 2022. TNX-13003 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the first half of 2022. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer. Tonix’s lead immunology candidate, TNX-15001, is a humanized monoclonal antibody targeting CD40 ligand being developed for the prevention of allograft rejection and the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to start in the second half of 2022. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox, next-generation vaccines to prevent COVID-19 and an antiviral to treat COVID-19. Tonix’s lead vaccine program is TNX-801 (live horsepox virus for percutaneous administration) for preventing smallpox and monkeypox4. Horsepox is also the basis for Tonix’s recombinant pox vaccine (RPV) platform. Tonix’s lead vaccine candidates for COVID-19, TNX-1840 and TNX-18505, are live virus vaccines in development based on the RPV platform. Finally, TNX-35006 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development.

1TNX-1500 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.

2TNX-102 SL is an investigational new drug and has not been approved for any indication.

3TNX-1300 is an investigational new biologic and has not been approved for any indication.

4TNX-801 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.

5TNX-1840 and TNX-1850 are investigational new biologics at the pre-IND stage of development and have not been approved for any indication. TNX-1840 and TNX-1850 are designed to express the spike protein of SARS-CoV-2 from omicron and BA.2 variants, respectively, based on the experience from TNX-1800, which expresses the spike protein from the ancestral Wuhan strain.

6TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

PainReform (PRFX) Scheduled to Present at NobleCon18 Investor Conference


PainReform CEO Ilan Hadar provides a preview of their upcoming presentation at NobleCon18

NobleCon18 – Noble Capital Markets 18th Annual Small and Microcap Investor Conference – April 19-21, 2022 – Hard Rock, Hollywood, FL 100+ Public Company Presentations | Scheduled Breakouts | Panel Presentations | High-Profile Keynotes | Educational Sessions | Receptions & Networking Events

Free Registration Available – More Info


News and Advanced Market Data on FLHLF


About PainReform

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company’s lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The Company’s proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit www.painreform.com.

The Case for More US Produced Uranium



Image: Fronteras desk (Flickr)


The Good News and Bad News Surrounding US Uranium Self-Reliance

 

Is the Russia/Ukraine war providing cause to become more self-reliant producing reactor-grade uranium? Uranium can be mined in many parts of the world, but the processing that allows the reactive mineral to be used as fuel is done in just a few spots on the globe. Currently, a full 20% of electricity in the US is generated from nuclear fuel. Russia has a hand in the production of a lot of it.

 

Background

Enriched uranium is mined, milled, converted into a gas, then enriched to increase the percentage of the isotope to 3%-5% before rods for fuel can be created.

Each of the steps takes place at specialized facilities. Up until recently, with the reliance on nuclear power diminishing and decades of the power source largely being written out of the power production future, there was no incentive for companies along the U308 supply chain to grow their operations. And mining slowed as raw uranium prices were seen as too low to compete with cheaper imports.

Russian uranium enrichment accounts for around 35% of the global market. In fact, the only commercial plants for uranium conversion into gas are in Russia, France, and Canada. There was a plant operating in Illinois that was mothballed but is scheduled to rejoin this part of the uranium supply chain in 2023.

 

Price Increase

Russia enriches more uranium for use in nuclear plants than any other country. Russia’s invasion of neighboring Ukraine has shaken the global market, as sanctions, and potential sanctions have increased the scarcity of many resources, including uranium. The risk to US energy generation of relying on all or part of the production to be outside North America has suddenly become apparent. Talk of ramping up domestic production has increased, but it can’t occur overnight.

 

Using $URA as price proxy, Price increase since January 27, 2022

 

Uranium prices have risen more than 30% since the start of the war, and 40% since the beginning of the threat. Each part of the refining process, from mining the raw material to the enriching processes have experienced price increases.

While further sanctions cause utilities to lock in future needs, a trade agreement has been in place that limits US dependence on Russian uranium to no more than around 20% of domestic reactors demand. That is certainly better than a much higher percentage as the US isn’t fully reliant.  But no other country could quickly fill Russia’s role in the supply chain for US usage. Another positive is US plants generally refuel every 18 to 24 months and plan for this at least two to three years in advance. So there is little concern in the short run for existing plants running out. There is time to prepare.

 

Opportunity

Does this create an opportunity in the stock market? Many of the forces that are weighing on some sectors of the stock market are having a positive impact on North American uranium mining stocks.

There are a number of companies that are involved in uranium production that were becoming interesting before the recent supply chain problems related to the Russian invasion. The segment was getting much attention as a result of the plans of companies to build modern, smaller nuclear reactors. The sudden change in the market landscape has now caused some of these companies’ stocks to experience price increases well in excess of that of physical uranium or uranium futures contracts.

 

 

One such company is Energy Fuels (UUUU). Energy Fuels is the largest uranium producer in the US and holds more production capacity and uranium resources than any other US producer. The current market cap is $1.6 billion. The movement on UUUU for the same period that Uranium ran up near 40%, has pushed the stock price of this producer up near 80% since late January.

On March 17, Noble Capital Markets Senior Energy Analyst Michael Heim released a report on $UUUU titled Ramp Up is Coming Slowly but
Higher Prices Could Spur Activity
. The report profiles the analyst’s view on the company and prospects in light of the changing market.

 

Take-Away

Uranium investments, whether a trust, a producer, or an ETF that tracks uranium prices have all been seeing an upsurge in interest. Part of this has been the move toward non-carbon-based energy and new generation modular plants being built.

The current understanding of how vulnerable the US is as a result of its offshoring much of the acquisition and processes to produce nuclear fuel, is likely to reshuffle where US plants fulfill most of their need in years to come. And those needs are expected to be increasing.

Channelchek is a great resource to analyze companies involved in this mining and energy segment. No cost sign-up provides full access to the website and research, including videos specific to uranium producers.

 

Suggested Reading



Has Uranium Demand Changed with Russia Ukraine War?



Is it Too Late to Benefit from Higher Oil?





Uranium and Natural Gas Investments Turn Green in 2023



Investor Information on Three Segments of the Uranium Energy Sector

 

Sources

https://www.uxc.com/p/products/spl_cesa.aspx

https://www.wsj.com/articles/u-s-rethinks-uranium-supply-for-nuclear-plants-after-russias-invasion-of-ukraine-11647941401

https://www.eia.gov/energyexplained/nuclear/where-our-uranium-comes-from.php

https://tradingeconomics.com/commodity/uranium

 

Stay up to date. Follow us:

 

Lineage Cell Therapeutics (LCTX) – New Addition To Product Pipeline in Hearing Loss

Tuesday, March 22, 2022

Lineage Cell Therapeutics (LCTX)
New Addition To Product Pipeline in Hearing Loss

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    A New Pipeline Product Has Been Added.  Lineage Cell announced that it has added a new program in auditory neuronal cell transplants for the treatment of hearing loss. The new development program will treat disorders in which the ear can detect sound, but the transmission of impulses to the brain is impaired.

    Cellular-Based Therapy Would Address An Unmet Need The new product would be based on the the company’s proprietary technology in which cultivated cells are transplanted to repair cells damaged or lost to disease.  Implanting auditory neurons could help restore hearing in conditions caused by nerve impairment in which cochlear implants and prosthetic devices are ineffective …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Release – Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference



Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

Research, News, and Market Data on Cocrystal Pharma

 

BOTHELL, Wash., March 22, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in the 2022 Virtual Growth Conference, presented by Maxim Group and hosted by M-Vest, being held March 28-30, 2022. Those interested in attending the virtual conference can register here.

A pre-recorded company presentation will be available on the M-Vest platform for 72 hours beginning March 28 at 9:00 a.m. Eastern time and can be accessed here. An archived webcast of the presentation will be available on the IR Calendar page of the company website.

Maxim Group LLC is a leading full-service investment bank, securities and wealth management firm headquartered in mid-town Manhattan and is a registered broker-dealer with the SEC and the Municipal Securities Rulemaking Board (MSRB) and is a member of FINRA and SIPC. M-Vest is a division of Maxim Group LLC that serves to allow investors to access investment opportunities online and to provide a digital community built for issuers, investors, and thought leaders to share information.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com

Source: Cocrystal Pharma, Inc.

Release – Delta Air Lines Signs 75 Million Gallon Per Year Agreement with Gevo



Delta Air Lines Signs 75 Million Gallon Per Year Agreement with Gevo

Research, News, and Market Data on Gevo

 

ENGLEWOOD, Colo., March 22, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) has signed a “take-or-pay” agreement with Delta Air Lines, Inc. (NYSE: DAL) to supply 75 million gallons of sustainable aviation fuel (SAF) per year for seven years (the “Agreement”). Based on current assumptions, including those around future pricing of commodities and the future values of certain environmental benefits, Gevo estimates that the Agreement should generate approximately $2.8 billion of revenue, inclusive of the value from environmental benefits, for Gevo over the seven-year term of the Agreement.

The Agreement replaces the existing agreement signed with Delta in 2019 to purchase 10 million gallons per year and bolsters Delta’s commitment to incorporating SAF into its operations.

“On behalf of the entire team at Gevo, I want to congratulate our partners at Delta for their leadership in continuously pushing the aviation industry towards net-zero emissions. Delta makes for a great customer, recognizing that big change is needed. I also appreciate their faith in what we are doing at Gevo. Net-zero jet fuels matter. We expect production from our first Net-Zero plant to begin in 2025. To meet the demand that we now have under contract, we need to develop and build more than one Net-Zero plant. This is a happy problem to have,” said Patrick R. Gruber, Ph.D., Gevo’s Chief Executive Officer.

“Net-Zero Fuels are made by using low-carbon feedstocks produced with climate-smart agricultural practices and by eliminating fossil-based energy from the business system as much as possible. In addition, our customers depend on us to count carbon at every step of the process,” said Paul D. Bloom, Ph.D., Gevo’s Chief Carbon Officer, and Chief Innovation Officer. Dr. Bloom continued, “By accurately accounting for carbon emissions using Argonne National Laboratories GREET model along with our Verity Tracking platform we will provide confidence to our customers like Delta that scientifically robust and transparent methods are used to meet and measure their sustainability goals. We want to create a win-win value proposition for every participant in the SAF supply chain by tracking all carbon intensity benefits in our SAF.”

“SAF is a critically important lever we have available today to help our industry reduce the lifecycle carbon emissions from aviation fuel,” said Kelly Nodzak, Delta’s Director of Global Jet Fuel Procurement. “That’s why we are working to develop the market and a broader understanding of the effectiveness of SAF, which can reduce lifecycle emissions up to 80 percent when used in pure form compared to fossil jet fuels.”

“With the right policies and incentives in place, we can unlock a future where sustainable aviation fuel is a viable climate solution that benefits air travel and beyond,” said Amelia DeLuca, Delta’s Vice President of Sustainability. “SAF production creates good-paying jobs in manufacturing, improves the environmental quality for all, and fosters rural economic opportunity for feedstocks and pathways. It will help us protect the planet we share and the places we call home.”

Gevo has remained focused on sustainability at every stage of production. Gevo has developed two alcohol-to-jet pathways that can utilize various low-carbon feedstocks grown using sustainable agriculture. These feedstocks can then be converted, in some cases, to high-value nutritional products and energy-dense liquid hydrocarbons, including SAF. Gevo’s production processes will incorporate renewable energy, including wind turbines, biogas, and combined heat and power systems (CHP) to increase efficiency and reduce carbon intensity to net-zero levels, which the customer can then pass on through the fuel.

The Agreement is subject to certain conditions precedent, including Gevo developing, financing and constructing one or more production facilities to produce the SAF contemplated by the Agreement. A copy of the Agreement between Delta and Gevo has been filed with the U.S. Securities and Exchange Commission on Form 8-K.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel, and diesel fuel, that when burned, have the potential to yield net-zero greenhouse gas emissions when measured across the full life cycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their life cycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low-carbon products such as gasoline components, jet fuel, and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Learn more at Gevo’s website: www.gevo.com

About Delta Air Lines

Delta’s commitment to sustainability is about joining arms to create a better world. The airline’s ambitious commitment to carbon neutrality from March 2020 onward is coming to fruition with swift impact through immediate actions, coupled with long-term investments to combat climate change. These investments will drive innovation, advance clean air travel technologies, accelerate the reduction of carbon emissions and waste, and establish a path to a more sustainable future. As a company driven by purpose, we hold ourselves to a high standard of producing sustainable, responsible financial results while investing in healthy communities, maintaining a diverse and inclusive workforce, and protecting natural environments. These values drive our overall approach to Environmental, Social, and Governance (ESG) sustainability and responsibility.

Learn more at the Delta Air Lines website: www.delta.com/

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, without limitation, including the Agreement, Delta’s purchase of SAF from Gevo, Gevo’s ability to produce SAF, Gevo’s estimate of the revenue that might be generated from the Agreement, Gevo’s ability to produce SAF and other fuels with a net-zero carbon intensity, Gevo’s technology, Gevo’s development, financing and construction of production facilities to produce SAF, the attributes of Gevo’s products, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2021, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Gevo Investor and Media Contact

Heather L. Manuel

+1 720-418-0085

IR@gevo.com

FAT Brands Inc. (FAT) – Growth Continues in the Fourth Quarter

Tuesday, March 22, 2022

FAT Brands Inc. (FAT)
Growth Continues in the Fourth Quarter

FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, and acquires predominantly fast casual restaurant concepts. The company provides turkey burgers, chicken Sandwiches, chicken tenders, burgers, ribs, wrap sandwiches, and others. Its brand portfolio comprises Fatburger, Buffalo’s Cafe and Express, and Ponderosa and Bonanza. The company’s overall footprint covers nearly 32 countries. Fatburger generates maximum revenue for the company.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    4Q21 Results. Fat Brands reported 4Q21 revenue of $74.2 million, up from $29.8 million in the third quarter and compared to $6.5 million in 4Q20. The increased revenue reflects the GFG and Twin Peaks acquisitions and about 10 days of revenue from the Fazoli’s and Native acquisitions. FAT reported adjusted EBITDA of $10.4 million in 4Q21. Net loss for the quarter was $19.6 million, or $1.38 per share, compared to a net loss of $3.6 million, or $0.26 per share in 3Q21 and a net loss of $7.7 million, or $0.64 per share, in 4Q20.

    Solid Growth.  Same store sales in the quarter rose 5.6% over the fourth quarter of 2019 and were up 8.5% if the recent acquisitions were included. Thirty new locations were opened during the quarter, bringing the full year count to 115. FAT ended the year with 2,369 locations, 761 franchise partners, and 333 multi-unit franchisees …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Digerati Technologies (DTGI) – A Surprising Reaction To A Solid Quarter Raising Price Target

Tuesday, March 22, 2022

Digerati Technologies (DTGI)
A Surprising Reaction To A Solid Quarter; Raising Price Target

Digerati Technologies, Inc. (OTCQB: DTGI) is a telecom and technology provider of diverse, carrier-grade, Only in the Cloud™ communication and network solutions including Unified Communication as a Service, cloud telephony, cloud WAN, cloud call center, cloud mobile, and delivery of digital oxygen on its fiber/mobile broadband network. Digerati has developed a robust integration platform to fuel mergers and acquisitions in a highly fragmented market as it delivers flexible, cost-effective services with enterprise-grade quality and reliability. A multi-year recipient of Deloitte’s Fast500 and Fast50 Awards for one of the fastest growing technology companies in North America, Digerati has become an expert at successfully merging and managing subsidiary operations since 2015. The Company’s impressive tech-stack serves 28,000 business users on its platform and its dynamic channel program includes over 300 channel partners that serve as a conduit for sales growth. Digerati has continuously increased customer adoption while serving diverse industries including Healthcare, Banking, Financial Services, Legal, Real Estate, and Construction. Digerati currently has a strong platform for growth throughout Texas and Florida, the 2nd and 4th largest state economies by GDP in the U.S. The Company’s clean and clear fundamentals, combined with its clearly defined growth plan, disciplined acquisition strategy and seasoned leadership team is expected to increase shareholder value as it enters the next phase of its corporate development plan. For more information, please visit www.digerati-inc.com.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Solid Q2 results.  Digerati reported better than expected fiscal second quarter end January 31 results, with total company revenues of $4.019 million, versus our $3.790 million estimate. Adj. EBITDA was also better than expected at $0.364 million versus our $0.309 million estimate. The results benefited from one month contribution from the Skynet acquisition, but results were better than expected after adjusting for that contribution.

    Executing the roll-up strategy.  The company has completed two acquisitions since the start of the year, SkyNet Telecom and Next Level. These acquisitions have augmented its customer reach in Texas and expanded operations into California. and now serves over 4,000 business customers and 45,000 users …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.